Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):344–351. doi: 10.1054/bjoc.2000.1614

Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma

H W Woitge 1, M Pecherstorfer 3, E Horn 3, A-V Keck 3, I J Diel 2, P Bayer 3, H Ludwig 3, R Ziegler 1, M J Seibel 1
PMCID: PMC2363749  PMID: 11161399

Abstract

To test the potential of immunoreactive BSP, a non-collagenous bone matrix component, as a clinical guide in patients with plasma cell dyscrasias, serum BSP concentrations were measured in 62 patients with newly diagnosed multiple myeloma (MM) followed over a period of 4 years, in 46 patients with monoclonal gammopathy of undetermined significance (MGUS), in 71 patients with untreated benign vertebral osteoporosis (OPO), and in 139 healthy adults. Results were compared with clinical and laboratory data, including serum osteocalcin (OC), and urinary pyridinoline (PYD) and deoxypyridinoline (DPD) as markers of bone turnover. In MM, serum BSP, and urinary PYD and DPD were higher than in healthy controls and in MGUS or OPO (P< 0.001). BSP levels correlated with the bone marrow plasma cell content (r = 0.40, P< 0.001), and serum β2-microglobulin (r = 0.31, P < 0.01). The differentiation of MM from healthy controls and from MGUS or OPO was highest for BSP. After chemotherapy, BSP reflected the response to treatment and correlated with the change in monoclonal protein (r = 0.55, P< 0.001). MM patients with normal baseline BSP levels survived longer than patients with initially elevated BSP values (P< 0.001, logrank test). Only serum monoclonal protein and BSP were independent predictors of survival. We conclude that in MM, BSP levels are associated with skeletal involvement and tumour cell burden. The quantification of serum BSP may be a non-invasive method for the diagnosis and follow-up, and may improve the prognostic value of conventional staging in MM. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: bone sialoprotein, multiple myeloma, tumour burden, neoplastic bone involvement, prognosis

Full Text

The Full Text of this article is available as a PDF (241.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bataille R., Chappard D., Alexandre C., Dessauw P., Sany J. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer. 1986 Jun;53(6):805–810. doi: 10.1038/bjc.1986.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bataille R., Chappard D., Basle M. F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood. 1996 Jun 1;87(11):4762–4769. [PubMed] [Google Scholar]
  3. Bataille R., Chappard D., Marcelli C., Dessauw P., Baldet P., Sany J., Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991 Jul;88(1):62–66. doi: 10.1172/JCI115305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 1989 Dec;7(12):1909–1914. doi: 10.1200/JCO.1989.7.12.1909. [DOI] [PubMed] [Google Scholar]
  5. Bataille R., Delmas P. D., Chappard D., Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer. 1990 Jul 1;66(1):167–172. doi: 10.1002/1097-0142(19900701)66:1<167::aid-cncr2820660130>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  6. Bataille R., Manolagas S. C., Berenson J. R. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 1997 Apr;11(2):349–361. doi: 10.1016/s0889-8588(05)70435-4. [DOI] [PubMed] [Google Scholar]
  7. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res. 1996 May;11(5):665–670. doi: 10.1002/jbmr.5650110514. [DOI] [PubMed] [Google Scholar]
  8. Bellahcène A., Merville M. P., Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 1994 Jun 1;54(11):2823–2826. [PubMed] [Google Scholar]
  9. Black D., Duncan A., Robins S. P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem. 1988 Feb 15;169(1):197–203. doi: 10.1016/0003-2697(88)90274-6. [DOI] [PubMed] [Google Scholar]
  10. Chen J. K., Shapiro H. S., Wrana J. L., Reimers S., Heersche J. N., Sodek J. Localization of bone sialoprotein (BSP) expression to sites of mineralized tissue formation in fetal rat tissues by in situ hybridization. Matrix. 1991 Apr;11(2):133–143. doi: 10.1016/s0934-8832(11)80217-9. [DOI] [PubMed] [Google Scholar]
  11. Coleman R. E. Skeletal complications of malignancy. Cancer. 1997 Oct 15;80(8 Suppl):1588–1594. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z. [DOI] [PubMed] [Google Scholar]
  12. Diel I. J., Solomayer E. F., Seibel M. J., Pfeilschifter J., Maisenbacher H., Gollan C., Pecherstorfer M., Conradi R., Kehr G., Boehm E. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res. 1999 Dec;5(12):3914–3919. [PubMed] [Google Scholar]
  13. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  14. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fisher L. W., Hawkins G. R., Tuross N., Termine J. D. Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem. 1987 Jul 15;262(20):9702–9708. [PubMed] [Google Scholar]
  16. Fisher L. W., Whitson S. W., Avioli L. V., Termine J. D. Matrix sialoprotein of developing bone. J Biol Chem. 1983 Oct 25;258(20):12723–12727. [PubMed] [Google Scholar]
  17. Fujisawa R., Butler W. T., Brunn J. C., Zhou H. Y., Kuboki Y. Differences in composition of cell-attachment sialoproteins between dentin and bone. J Dent Res. 1993 Aug;72(8):1222–1226. doi: 10.1177/00220345930720081001. [DOI] [PubMed] [Google Scholar]
  18. Heinegård D., Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J. 1989 Jul;3(9):2042–2051. doi: 10.1096/fasebj.3.9.2663581. [DOI] [PubMed] [Google Scholar]
  19. Helfrich M. H., Nesbitt S. A., Dorey E. L., Horton M. A. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res. 1992 Mar;7(3):335–343. doi: 10.1002/jbmr.5650070314. [DOI] [PubMed] [Google Scholar]
  20. Karmatschek M., Maier I., Seibel M. J., Woitge H. W., Ziegler R., Armbruster F. P. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem. 1997 Nov;43(11):2076–2082. [PubMed] [Google Scholar]
  21. Mundy G. R., Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998 Aug 6;339(6):398–400. doi: 10.1056/NEJM199808063390609. [DOI] [PubMed] [Google Scholar]
  22. Oldberg A., Franzén A., Heinegård D., Pierschbacher M., Ruoslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem. 1988 Dec 25;263(36):19433–19436. [PubMed] [Google Scholar]
  23. Pecherstorfer M., Seibel M. J., Woitge H. W., Horn E., Schuster J., Neuda J., Sagaster P., Köhn H., Bayer P., Thiébaud D. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood. 1997 Nov 1;90(9):3743–3750. [PubMed] [Google Scholar]
  24. Raynal C., Delmas P. D., Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology. 1996 Jun;137(6):2347–2354. doi: 10.1210/endo.137.6.8641185. [DOI] [PubMed] [Google Scholar]
  25. Ross F. P., Chappel J., Alvarez J. I., Sander D., Butler W. T., Farach-Carson M. C., Mintz K. A., Robey P. G., Teitelbaum S. L., Cheresh D. A. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993 May 5;268(13):9901–9907. [PubMed] [Google Scholar]
  26. Seibel M. J., Woitge H. W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., Armbruster F. P., Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab. 1996 Sep;81(9):3289–3294. doi: 10.1210/jcem.81.9.8784085. [DOI] [PubMed] [Google Scholar]
  27. Shapiro H. S., Chen J., Wrana J. L., Zhang Q., Blum M., Sodek J. Characterization of porcine bone sialoprotein: primary structure and cellular expression. Matrix. 1993 Nov;13(6):431–440. doi: 10.1016/s0934-8832(11)80109-5. [DOI] [PubMed] [Google Scholar]
  28. Teoh G., Anderson K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997 Feb;11(1):27–42. doi: 10.1016/s0889-8588(05)70413-5. [DOI] [PubMed] [Google Scholar]
  29. Uchiyama H., Barut B. A., Mohrbacher A. F., Chauhan D., Anderson K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993 Dec 15;82(12):3712–3720. [PubMed] [Google Scholar]
  30. Van Riet I., Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma. 1993 Apr;9(6):441–452. doi: 10.3109/10428199309145751. [DOI] [PubMed] [Google Scholar]
  31. Van Riet I., Vanderkerken K., de Greef C., Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Med Oncol. 1998 Sep;15(3):154–164. doi: 10.1007/BF02821934. [DOI] [PubMed] [Google Scholar]
  32. Waltregny D., Bellahcène A., Van Riet I., Fisher L. W., Young M., Fernandez P., Dewé W., de Leval J., Castronovo V. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst. 1998 Jul 1;90(13):1000–1008. doi: 10.1093/jnci/90.13.1000. [DOI] [PubMed] [Google Scholar]
  33. Woitge H. W., Pecherstorfer M., Li Y., Keck A. V., Horn E., Ziegler R., Seibel M. J. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999 May;14(5):792–801. doi: 10.1359/jbmr.1999.14.5.792. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES